Research company Hamlet Biopharma preliminarily raises approximately SEK 25.7 million before issue costs through the exercise of Series TO5B warrants. In total, just over 4.3 million new B shares were preliminarily subscribed for at a subscription price of SEK 6, corresponding to a subscription rate of approximately 79 percent.The outcome is preliminary because a transaction worth approximately SEK 1.8 million has not yet been completed for administrative reasons, according to the company.